Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pain At The Pump: For Some VCs, Filling Up On Cash Is Easier Than For Others

This article was originally published in Start Up

Executive Summary

Who has recently topped up, and who’s running on empty? START-UP’s annual gas-tank review of venture fundraising shows how consolidation has hit the sector hard in the past twelve months, as limited partners concentrate their money in specialized funds that have demonstrated an ability to deliver returns.

You may also be interested in...

Life Sciences VCs Leave Morgenthaler, ATV To Form New Fund

The two teams will exit their hybrid funds and raise capital for a new vehicle intended solely for life sciences startups.

Sofinnova Ventures' New $440M Eighth Fund Exceeds Expectations And Makes Adjustments

The firm wins higher commitments from limited partners, turning its health-care focus to late stage companies and forgoing high-tech investments.

Some VC Funds Have Miles To Go While Others Have Burned What's In The Tank

The slowdown and shake-out predicted to occur in the world of venture capital has come. But has it also already gone, too? The industry has certainly retrenched, but there are also signs of new life in the venture sector. For the past two years, we've tracked a few dozen life sciences firms, with an eye on which ones have nearly tapped out their older funds and which have fresh cash to invest in young start-ups. Here's an updated look at the venture fund landscape, showing the firms with full tanks and the ones who are running on empty, based on SEC filings, firm announcements, and our own database and reporting.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts